The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | T-Cell lymphoma: implications of interleukin-10 loss
Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the challenges of treating adult T-cell leukemia/lymphoma (TCL). Prof. Bazarbachi outlines the results of a study that demonstrated that arsenic trioxide (AS) and interferon-α (IFNα)-induced abrogation of leukemia-initiating cell activity requires IL-10 expression shutoff in patients with adult TCL. This loss of IL-10 results in increased production of inflammatory cytokines, resulting in innate immunity-mediated clearance of Tax-driven leukemic cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
